$VKTX TRUIST $LLY data is impressive, but highlight 3 key findings, all of which may be related to glucagon MOA, which gives us pause on retatrutide's MOA:CV imbalance, specifically arrhythmias in drug arm Evidence of anti-drug antibody (ADA)&hypersensitivity BMO - who has some best coverage of $LLY & obesity market dynamics - clearly points out safety concerns especially in high dose Retatrutide
For a medicine to earn clear dosing guidance, researchers generally need repeated studies, defined outcomes, safety data, and a regulated product
This is an individual decision based on your metabolic profile, biomarkers, weight regain risk, and treatment goals
It all comes down to a simple, powerful formula: Protein + Fat + Fiber, or PFF for short